• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Jayson, Gordon C
    Zweit, Jamal
    Jackson, Alan
    Mulatero, Clive
    Julyan, Peter J
    Ranson, Malcolm R
    Broughton, Lynn
    Wagstaff, John
    Hakannson, L
    Groenewegen, Gerard
    Bailey, John
    Smith, Nigel K
    Hastings, David L
    Lawrance, Jeremy A L
    Haroon, Hamied
    Ward, Timothy H
    McGown, Alan T
    Tang, Meina
    Levitt, Dan
    Marreaud, Sandrine
    Lehmann, Frederic F
    Herold, Manfred
    Zwierzina, Heinz
    Show allShow less
    Affiliation
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. Gordon.Jayson@christie-tr.nwest.nhs.uk
    Issue Date
    2002-10-02
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine, and various inhibitory agents, including specific antibodies, have been developed to block VEGF-stimulated angiogenesis. We developed HuMV833, a humanized version of a mouse monoclonal anti-VEGF antibody (MV833) that has antitumor activity against a number of human tumor xenografts, and investigated the distribution and biologic effects of HuMV833 in patients in a phase I trial. METHODS: Twenty patients with progressive solid tumors were treated with various doses of HuMV833 (0.3, 1, 3, or 10 mg/kg). Positron emission tomography with (124)I-HuMV833 was used to measure the antibody distribution in and clearance from tissues. Magnetic resonance imaging was used to measure the vascular permeability surface area product with a first-pass pharmacokinetic model (k(fp)) to determine tumor vascular permeability. RESULTS: The antibody was generally well tolerated, although the incremental dose, phase I study design, and pharmacodynamic endpoints could not identify the optimum biologically active dose. Antibody distribution and clearance were markedly heterogeneous between and within patients and between and within individual tumors. HuMV833 distribution to normal tissues also varied among patients, but the antibody was cleared from these tissues in a homogeneous fashion. Permeability was strongly heterogeneous between and within patients and between and within individual tumors. All tumors showed a reduction in k(fp) 48 hours after the first treatment (median = 44%; range = 4%-91%). CONCLUSIONS: Because of the heterogeneity in tumor biology with respect to antibody uptake and clearance, we suggest that either intrapatient dose escalation approaches or larger, more precisely defined patient cohorts would be preferable to conventional strategies in the design of phase I studies with antiangiogenic compounds like HuMV833.
    Citation
    Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. 2002, 94 (19):1484-93 J. Natl. Cancer Inst.
    Journal
    Journal of the National Cancer Institute
    URI
    http://hdl.handle.net/10541/81265
    PubMed ID
    12359857
    Type
    Article
    Language
    en
    ISSN
    0027-8874
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.